Thomas A Paterniti

Dr. Thomas A Paterniti

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 October 2021 in Obstetrics & Gynecology
Verified
Journal Article
Closed access
TPThomas A Paterniti
Thomas A Paterniti
KDKatie Dorr
Katie Dorr
AUAsad Ullah
Asad Ullah
JWJoseph Do White
Joseph Do White
HWHadyn Williams
Hadyn Williams
SGSharad Ghamande
Sharad Ghamande
BACKGROUND: Small cell neuroendocrine carcinoma of the cervix is a rare, aggressive tumor treated with a combination of surgery, chemotherapy, and radiation. Survival rates are poor, and innovative therapies are needed. CASE: A 52-year-old woman was diagnosed with small cell neuroendocrine carcinoma of the cervix. Over a 10-year period, she was treated with six different systemic therapeutic regimens, underwent planned hysterectomy with bilateral salpingo-oophorectomy, and received radiation to the pelvis and brain. After a second recurrence of disease, she was treated with a combination of nivolumab and ipilimumab and experienced a complete and durable response. CONCLUSION: The combination of nivolumab and ipilimumab may represent a promising new treatment option for recurrent small cell neuroendocrine carcinoma of the cervix.

24 January 2020 in Clinical Pediatrics
Verified
Journal Article
Open access
PDF file
ESEvan Schrader
Evan Schrader
ADAbigail D. Delehanty
Abigail D. Delehanty
ACAlix Casler
Alix Casler
EPErin Petrie
Erin Petrie
ARAlexa Rivera
Alexa Rivera
AWAmy M. Wetherby
Amy M. Wetherby

20 August 2024 in Surgeries
Verified
Journal Article
Open access
PDF file
Asad UllahAsad Ullah
Asad Ullah
LRLily Rubin
Lily Rubin
ARAlexa Rakusin
Alexa Rakusin
AYAbdul Qahar Khan Yasinzai
Abdul Qahar Khan Yasinzai
ACAbdullah Bin-Saleem Chandasir
Abdullah Bin-Saleem Chandasir
MRMark B Reedy
Mark B Reedy
Introduction: Uterine carcinosarcoma is an aggressive gynecologic malignancy that accounts for 5% of all gynecological malignancies. There is a disproportion in its incidence and mortality among different races. This study describes demographic and clinicopathological factors and racial disparities affecting the survival of patients with uterine carcinosarcoma. Methods: Data on uterine carcinosarcoma patients were obtained from the Surveillance, Epidemiology, and End Results (SEER) database from 2000 to 2020. Results: Of the 11,338 patients identified, the median age at diagnosis was 68 years, and the five-year cause-specific survival (CSS) rate was 38.7%. for all races. Compared with Asian patients (39.5%, 95% CI, 36.0–43.4%), Hispanic patients (39.4%, 95% CI, 36.5–42.5%), and White patients (37.9%, 95% CI, 36.7–39.2%), Black patients accounted for 21% of the patients and had a significantly lower 5-year CSS (95% CI, 27.2–31.2%). The CSS rates were 84.4% (95% CI, 83.3–85.6%) for localized tumors, 68.5% (95% CI, 66.9–70.1%) for regional tumors, and 39.0% (95% CI, 36.9–41.2%) for distant tumors. Multimodal treatment involving chemotherapy, surgery, and radiation improved the overall one- and five-year survival rates by 88.2% (95% CI, 87.0–89.5%) and 52.8% (95% CI, 50.7–55.1%), respectively, across all disease stages. Multivariate analysis identified age >60 years, Black race, tumor size >4 cm, and distant metastases as independent risk factors for mortality (p < 0.0001). Conclusions: This large database study presents the most up-to-date epidemiological information regarding cases of uterine carcinosarcoma. The findings suggest that a combination of surgery, chemotherapy, and radiation may be most efficacious in treating this malignancy, especially in patients with distant disease.

30 September 2021 in North American Proceedings in Gynecology & Obstetrics
Verified
Journal Article
Open access
PDF file
KSKasey Shepp
Kasey Shepp
TPThomas A Paterniti
Thomas A Paterniti
DKDiana Kozman
Diana Kozman
WFWilliam Forehand
William Forehand
TATania K. Arora
Tania K. Arora
RPRenee Page
Renee Page
**Background:** Gastrointestinal stromal tumors are rare in pregnancy, and typically present in the second trimester with size-greater-than-dates, abdominal pain, or nonspecific symptoms. **Case:** A 31-year-old gravida 1 female presented in the postpartum period with weight loss, cachexia, an abdominal mass, and persistent unexplained tachycardia. She was found to have a recurrent metastatic gastrointestinal stromal tumor and pulmonary emboli. She was anticoagulated and treated with neoadjuvant imatinib therapy with excellent initial response. Unfortunately, she died one year later due to complications of her disease and treatment. **Conclusion:** Malignancy should be considered in a pregnant woman with size-greater-than-dates or with an abdominal mass, especially when associated with unexplained weight loss and a history of a gastrointestinal stromal tumor, as the recurrence rate is high without continued maintenance therapy. Delivery at 35 to 37 weeks is recommended, and involvement of a multidisciplinary team improves outcomes.

15 April 2019 in Hospital Practices and Research
Verified
Journal Article
Open access
PDF file
TPThomas A Paterniti
Thomas A Paterniti
LWLee Weber
Lee Weber
GKGene Krishingner
Gene Krishingner
SASarfraz Ahmad
Sarfraz Ahmad
Introduction: Essure® device malposition is a rare, but clinically significant complication, for which management is idiosyncratic. This case report describes an unusual example of Essure® migration in order to clarify reasonable management options. Case Presentation: A 50-year old G4 P2022 underwent hysteroscopic sterilization using the Essure® device. Insertion was complicated by fragmentation of both coils. Two years later, one of the coils was incidentally discovered protruding through the cervical os. The visible portion was clipped when attempts to remove the entire coil were unsuccessful. Conclusion: Difficult placement increases the risk of Essure® malposition. In asymptomatic patients, conservative management with removal of only a portion of the device is a rational approach.

26 March 2022
Verified
Book Chapter
Closed access
PDF file
KSKasey Shepp
Kasey Shepp
ATAditi Talkad
Aditi Talkad
TPThomas A Paterniti
Thomas A Paterniti
APAlexandra M. Poch
Alexandra M. Poch
Sarfraz AhmadSarfraz Ahmad
Sarfraz Ahmad